혈액암 치료제 시장(-2030년)

The global market for blood cancer therapeutics was valued at $77.1 billion in 2025 and is projected to reach $125.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.

Report Scope

This report analyzes market trends for blood cancer therapeutics, providing data from 2024, 2025 estimates, compound annual growth rate projections through 2030 (forecast period: 2025-2030), and regional markets. It covers the market potential, competitive environment, regulatory scenarios, drivers, restraints, and opportunities, as well as market projections for 2030 and market share for key companies.

The market scope in this report is segmented by type into leukemia, lymphoma, multiple myeloma, and rare blood disorders. Leukemia is further subdivided into acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous (myeloid) leukemia (AML), and chronic myelogenous (myeloid) leukemia (CML). Lymphoma is further subdivided into non-Hodgkin lymphoma and Hodgkin lymphoma. Rare blood disorders include myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs).

The market has been segmented into significant geographies: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment will provide a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 and a 2030 forecast value.

The report aims to:

• Analyze types of blood cancer therapeutics.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the blood cancer therapeutics market.

Report Includes

• 88 data tables and 63 additional tables
• An overview and analysis of the global blood cancer therapeutics market
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the current market size and growth prospects, with a market share analysis by cancer type, therapeutic class, and region
• Facts and figures related to market dynamics, including key drivers, restraints, challenges, and opportunities
• Review of macroeconomic factors and insights derived from Porter's Five Forces analysis
• Overview of the regulatory landscape across North America, Europe, and Asia-Pacific
• Discussion of emerging technologies and developments, including clinical trials, pipeline analysis, and patent activity
• Detailed market analysis by blood cancer type, including leukemia, lymphoma, and multiple myeloma
• Regional market analysis covering North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, with country-level data
• Analysis of the competitive landscape, including company share analysis and strategic initiatives
• Company profiles of major players within the industry, including Johnson & Johnson, Bristol-Myers Squibb Co., AbbVie Inc., Novartis AG, and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Impact of Global Economic Growth (GDP) on the Pharma Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rise in Blood Cancer Cases
• Increasing Burden of Blood Cancers
• Rising R&D Investment Among Companies in the Market
• Increase in Government Funding and Pharmaceutical R&D Expenditures
• Market Restraints
• Rising Generic Competition and Patent Expiration
• Availability of Affordable Chemotherapeutics Restricts Growth of Advanced Therapies
• High Cost of Blood Cancer Therapeutics
• Market Opportunities
• Potential of Blood Cancer Therapeutics
• Emerging Markets
• Technological Advances in Drug Manufacturing

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence (AI)
• Antibody-Modified Nanosystems
• Targeted Drug Delivery
• Clinical Trial Analysis
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Blood Cancer Therapeutics, by Cancer Type
• Key Takeaways
• Lymphoma
• Leukemia
• Multiple Myeloma
• Rare Blood Cancers
• Global Market for Blood Cancer Therapeutics, by Therapeutic Type
• Key Takeaways
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Geographic Breakdown
• Global Market for Blood Cancer Therapeutics, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• Middle East
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis

Chapter 8 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• REGENERON PHARMACEUTICALS INC.
• SANOFI